Related Experiment Video
Updated: Mar 10, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Patient-derived induced pluripotent stem cells in cancer research and precision oncology
Eirini P Papapetrou1,2,3,4
1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Abstract:
Together with recent advances in the processing and culture of human tissue, bioengineering, xenotransplantation and genome editing, Induced pluripotent stem cells (iPSCs) present a range of new opportunities for the study of human cancer. Here we discuss the main advantages and limitations of iPSC modeling, and how the method intersects with other patient-derived models of cancer, such as organoids, organs-on-chips and patient-derived xenografts (PDXs). We highlight the opportunities that iPSC models can provide beyond those offered by existing systems and animal models and present current challenges and crucial areas for future improvements toward wider adoption of this technology.
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
Induced Pluripotent Stem Cells
EPS and iPS Cells in Disease Research
iPS Cell Differentiation
Stem Cell Culture

